KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Long-Term Debt Repayments (2016 - 2025)

Eli Lilly (LLY) has disclosed Long-Term Debt Repayments for 16 consecutive years, with -$100000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Debt Repayments rose 50.0% year-over-year to -$100000.0, compared with a TTM value of -$300000.0 through Dec 2025, down 50.0%, and an annual FY2025 reading of $778.0 million, up 17.17% over the prior year.
  • Long-Term Debt Repayments was -$100000.0 for Q4 2025 at Eli Lilly, up from -$200000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $1.9 billion in Q3 2021 and bottomed at -$200000.0 in Q4 2024.
  • Average Long-Term Debt Repayments over 4 years is $577.5 million, with a median of $355.1 million recorded in 2021.
  • The sharpest move saw Long-Term Debt Repayments tumbled 50.0% in 2021, then surged 50.0% in 2025.
  • Year by year, Long-Term Debt Repayments stood at $100000.0 in 2021, then soared by 849800.0% to $849.9 million in 2022, then plummeted by 100.02% to -$200000.0 in 2024, then soared by 50.0% to -$100000.0 in 2025.
  • Business Quant data shows Long-Term Debt Repayments for LLY at -$100000.0 in Q4 2025, -$200000.0 in Q4 2024, and $849.9 million in Q2 2022.